References
- American Cancer Society. Cancer facts and figures 2006
- Walboomers JMM, Jacobs MV, Manos MM, . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12–9
- Melnikow J, Nuovo J, Willan AR, . Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92: 727–35
- Christensen ND. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs 2005;10: 5–19
- Muñoz N, Bosch FX, de Sanjosé S, . Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Engl J Med 2003;348: 518–27
- Wiley DJ, Douglas J, Beutner K, . External genital warts: diagnosis, treatment and prevention. Clin Infect Dis 2002;35: S210–S224
- Paavonen J, Jenkins D, Bosch FX, . Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369: 2161–70
- Garland SM, Hernandez-Avila M, Wheeler CM, . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Engl J Med 2007;356: 1928–43
- The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New Engl J Med 2007;356: 1915–27
- Ferris DG; for the FUTURE II Study Group. Efficacy of a quadrivalent HPV (types 6/11/16/18) L1 virus-like particle (VLP) vaccine in women with viologic evidence of HPV infection: a combined analysis. Presented at the European Research Organization on Genital Infection and Neoplasia Annual Conference Paris, France 2006
- Collins S, Mazloomzadeh S, Winter H, . High incidence of cervical human papillomavirus infection in women during their first sexual relationship. Br J Obstet Gynaecol 2002;109: 96–8
- Mao C, Koutsky LA, Ault KA, . Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107: 18–27
- Villa LL, Costa RLR, Petta CA, . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncology 2005;6: 271–8
- Block SL, Nolan T, Sattler C, . Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118: 2135–45
- Dias D, Van Doren J, Schlottmann S, . Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin Diagn Lab Immunol 2005;12: 959–69
- Saslow D, Castle PE, Cox JT, . American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. Ca Cancer J Clin 2007;57: 7–28
- Dillner J, Kallings I, Brihmer C, . Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996;173: 1394–8
- Woodman CB, Collins S, Winter H, . Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357: 1831–6
- Eaton DK, Kann L, Kinchen S, . Youth risk behavior surveillance – United States, 2005. MMWR Surveill Summ 2006;55: 1–108
- Konya J, Dillner J. Immunity to oncogenic human papillomaviruses. Adv Cancer Res 2001;82: 205–38